Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven J Cohen

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|June 6, 2020
Racial Disparities in Rates of Surgery for Esophageal Cancer: a Study from the National Cancer DatabaseSamantha L Savitch, Tyler R Grenda, Walter Scott, et al.
The Oncologist|May 1, 2015
Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204Jerome C Landry, Yang Feng, Roshan S Prabhu, et al.
Cancer|January 5, 2013
Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204Jerome C Landry, Yang Feng, Steven J Cohen, et al.
Annals of Surgical Oncology|June 11, 2021
Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic AdenocarcinomaEddie Zhang, Lora Wang, Talha Shaikh, et al.
The Oncologist|August 18, 2018
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus <i>nab</i>-Paclitaxel and Gemcitabine in Advanced Solid TumorsGregory L Beatty, Safi Shahda, Thaddeus Beck, et al.
Clinical Colorectal Cancer|August 24, 2011
Assessing compliance with national comprehensive cancer network guidelines for elderly patients with stage III colon cancer: the Fox Chase Cancer Center Partners' initiativeMargaret A O'Grady, Elyse Slater, Elin R Sigurdson, et al.
Practical Radiation Oncology|March 29, 2014
Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinomaLauren M Tait, Joshua E Meyer, Erin McSpadden, et al.
Seminars in Oncology|January 10, 2006
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experienceAndre Konski, John Hoffman, Elin Sigurdson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2014
Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancerMohamedtaki A Tejani, Anna ter Veer, Dana Milne, et al.
Gastrointestinal Cancer Research : GCR|November 2, 2011
Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal CancerNavesh K Sharma, Joshua S Silverman, Tianyu Li, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|June 6, 2020
Racial Disparities in Rates of Surgery for Esophageal Cancer: a Study from the National Cancer DatabaseSamantha L Savitch, Tyler R Grenda, Walter Scott, et al.
The Oncologist|May 1, 2015
Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204Jerome C Landry, Yang Feng, Roshan S Prabhu, et al.
Cancer|January 5, 2013
Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204Jerome C Landry, Yang Feng, Steven J Cohen, et al.
Annals of Surgical Oncology|June 11, 2021
Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic AdenocarcinomaEddie Zhang, Lora Wang, Talha Shaikh, et al.
The Oncologist|August 18, 2018
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus <i>nab</i>-Paclitaxel and Gemcitabine in Advanced Solid TumorsGregory L Beatty, Safi Shahda, Thaddeus Beck, et al.
Clinical Colorectal Cancer|August 24, 2011
Assessing compliance with national comprehensive cancer network guidelines for elderly patients with stage III colon cancer: the Fox Chase Cancer Center Partners' initiativeMargaret A O'Grady, Elyse Slater, Elin R Sigurdson, et al.
Practical Radiation Oncology|March 29, 2014
Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinomaLauren M Tait, Joshua E Meyer, Erin McSpadden, et al.
Seminars in Oncology|January 10, 2006
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experienceAndre Konski, John Hoffman, Elin Sigurdson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2014
Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancerMohamedtaki A Tejani, Anna ter Veer, Dana Milne, et al.
Gastrointestinal Cancer Research : GCR|November 2, 2011
Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal CancerNavesh K Sharma, Joshua S Silverman, Tianyu Li, et al.
Pageof 11